
Aclaris Therapeutics (ACRS) Stock Forecast & Price Target
Aclaris Therapeutics (ACRS) Analyst Ratings
Bulls say
Aclaris Therapeutics is viewed favorably because its ATI-052 Phase 1b data showed strong proof-of-concept in both atopic dermatitis and asthma, with rapid efficacy signals, no Grade 3 or 4 adverse events, no conjunctivitis, and a safety profile that supports broader development. The atopic dermatitis readout was especially compelling, including a 45% placebo-adjusted mean EASI improvement, 78% placebo-adjusted EASI-50, and 95% normalization of the lesional skin proteome by week 8, while management believes quarterly dosing may be achievable versus Dupixent’s twice-monthly regimen. Financially, the company strengthened its balance sheet with an underwritten offering expected to raise about $50M and extend runway well into 2029, supporting continued development of ATI-052 and the rest of the pipeline.
Bears say
Aclaris Therapeutics is viewed negatively because bosakitug’s Phase II ADMIRATION study in atopic dermatitis missed both primary and secondary endpoints, undermining confidence in the company’s TSLP strategy and suggesting that target engagement alone may not translate into meaningful clinical benefit. The setback also weakens the rationale for ATI-052 in AD, where the analyst lowered probability of success estimates to 20% in the U.S. and 15% in the EU, while acknowledging growing competitive and regulatory risks in eosinophilic esophagitis. With modzatinib’s top-line data not expected until 2H27 and ATI-052’s Phase IIb EoE trial only planned for 1Q27, the pipeline remains highly speculative and delayed.
This aggregate rating is based on analysts' research of Aclaris Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Aclaris Therapeutics (ACRS) Analyst Forecast & Price Prediction
Start investing in Aclaris Therapeutics (ACRS)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Aclaris Therapeutics (ACRS) Forecast
Aclaris Therapeutics (ACRS) Analyst Forecast & Price Prediction
Start investing in Aclaris Therapeutics (ACRS)
Order type
Buy in
Order amount
Est. shares
0 shares